Terremoto Biosciences has launched with $75 million in series A financing to discover small-molecule drugs using its lysine-targeted covalency technology. Terremoto says most drugs that bind to ...
Misbehaving proteins are behind many diseases. One way drugmakers incapacitate these bad actors is to deploy molecules that bind to them. But finding solid footholds on the proteins to block their ...
The host immune "recognition" of cancer forms the basis of modern tumor immmunotherapy, a highly targeted treatment option with the demonstrated ability to "cure" previously lethal blood cancers.
Vividion announces publication on discovery and preclinical study of small molecules activating KEAP1 via a covalent molecular glue to degrade NRF2.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback